quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64

View original at finance.yahoo.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 McCormick & Company, Incorporated (NYSE:MKC) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY26 adjusted EPS guidance of $3.05-$3.13 versus $3.09 consensus

    60% confidence

  • The company delivered growth in sales, operating income, and earnings per share, supported by the McCormick de Mexico acquisition and organic growth across both segments, alongside cost discipline that drove margin expansion

    60% confidence

  • Expected revenue growth of 13%-17% for FY26

    60% confidence

  • Certain AI stocks offer greater upside potential and carry less downside risk than MKC

    60% confidence

  • McCormick price target lowered to $64 from $67 with Overweight rating maintained

    60% confidence

  • McCormick is not receiving the 'benefit of the doubt' from investors regarding its food deal

    60% confidence

  • Volumes were in line with expectations and anticipates sequential improvement through the year, supported by brand investments, innovation, and distribution gains

    60% confidence

  • Projected tax rate of 24% for FY26

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com